Nutritional treatment for acquired immunodeficiency virus infection using an enterotropic peptide-based formula enriched with n-3 fatty acids: a randomized prospective trial
- 1 December 2001
- journal article
- clinical trial
- Published by Springer Nature in European Journal of Clinical Nutrition
- Vol. 55 (12) , 1048-1052
- https://doi.org/10.1038/sj.ejcn.1601276
Abstract
Objective: Dietary counseling and intervention based on application of conventional criteria have been ineffective in preventing the progressive weight loss associated with HIV infection. The aim of the study was to compare the progression of clinical and nutritional indicators during nutritional supplementation with or without an enterotropic peptide-based formula enriched with n-3 fatty acids. Design: Randomized trial. Setting: Tertiary care. Subjects: Ninety-one patients were screened for the study. Twenty-three did not meet the inclusion criteria, therefore 74 patients were randomized. Of these, 38 were randomized to group I (standard formula) and 36 were randomized to group II supplementation (enterotropic peptide-based formula enriched with n-3 fatty acids). Interventions: Group I received standard enteral formula and group II received a enterotropic peptide-based enteral formula. The volume was the same (3 cans/day, 236 ml per can). In both groups enteral supplementation were recommended in conjunction with a registered dietitian under a dietary counseling program based on standard nutrition principles. Patients received a prospective serial assessment of nutrition status, nutritional intake with 24 h written food records, GI symptoms, immune function, anthropometric status and intercurrent health events including infections and hospitalization. These determinations were performed at baseline and at 3 months. Results: Treatment with both supplements resulted in a significant and sustained increase in weight (3.2% in group I and 3.1% in group II); this increase was mostly due to fat mass (12.8% in group I) and (7.5% in group II). Total body water and fat free-mass remained unchanged. CD4 counts remained stable in group I, while a significant increase was detected in group II (576±403 vs 642±394 cells/mm3; PEuropean Journal of Clinical Nutrition (2001) 55, 1048–1052Keywords
This publication has 14 references indexed in Scilit:
- Nutritional Treatment for Acquired Immunodeficiency Virus‐Associated Wasting Using β‐Hydroxy β‐Methylbutyrate, Glutamine, and Arginine: A Randomized, Double‐Blind, Placebo‐Controlled StudyJournal of Parenteral and Enteral Nutrition, 2000
- A randomized double-blind controlled study of 6 months of oral nutritional supplementation with arginine and Ω-3 fatty acids in HIV-infected patientsAIDS, 1998
- Glutamine deficiency as a cause of human immunodeficiency virus wastingMedical Hypotheses, 1996
- Whole-body protein turnover from leucine kinetics and the response to nutrition in human immunodeficiency virus infectionThe American Journal of Clinical Nutrition, 1995
- Prospective analysis of patterns of weight change in stage IV human immunodeficiency virus infectionThe American Journal of Clinical Nutrition, 1993
- Resting energy expenditure in human immunodeficiency virus-infected patients: comparison between patients with and without secondary infectionsThe American Journal of Clinical Nutrition, 1993
- Body composition in myelomeningoceleThe American Journal of Clinical Nutrition, 1991
- Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDSThe American Journal of Clinical Nutrition, 1989
- The Effect of Dietary Supplementation with n—3 Polyunsaturated Fatty Acids on the Synthesis of Interleukin-1 and Tumor Necrosis Factor by Mononuclear CellsNew England Journal of Medicine, 1989
- Malnutrition in HIV infection and AIDSAIDS, 1989